ClinicalTrials.gg
CompletedNCT06057012Updated Jan 27, 2025

A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)

A Phase 2 interventional study of BRII-296 and Depo Medrol in Severe Postpartum Depression, sponsored by Brii Biosciences Limited. Completed at 11 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Brii Biosciences Limited · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
181st of 198
11 · median 86
Started
2023
with 17 others
Phase 2
18 of 220
none open now
Registered
179th of 220
by date

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 181st largest by enrollment of the 198 interventional ones that give a count, is one of 18 that started in 2023, is one of 18 in phase 2, and was the 179th registered.

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the safety and tolerability of BRII-296 administered by 2 intramuscular injections, administered with Depo Medrol as assessed by the incidence of adverse events, changes from baseline in vital signs, pulse oximetry, clinical laboratory evaluations, electrocardiograms (ECGs), Stanford Sleepiness Scale (SSS), Glasgow Coma Scale (GCS) in conjunction with clinical assessment, and suicidal ideation using the Columbia Suicide Severity Rating Scale (C-SSRS).

03

Conditions studied

  • Severe Postpartum Depression

Keywords

  • Treatment
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant either must have ceased lactating at screening or is still lactating actively breastfeeding at screening , must agree temporarily cease giving breast milk to her infant(s)
  • Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for (DSM-5)
  • Participant was \<12 months postpartum
  • Participant is amenable to intramuscular administration of product on Day 1 and remaining inpatient until at least Day 4

Exclusion criteria

Exclusion Criteria:

  • Active psychosis
  • Attempted suicide associated with current episode of postpartum depression
  • Medical history of seizures
  • Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    BRII-296 + Depo Medrol

    Participants will receive BRII-296 600 milligram (mg) and Depo Medrol (80 milligram per milliliter \[mg/mL\]) on Day 1 as a combination therapy.

    Drug: BRII-296 · Drug: Depo Medrol

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From the first dose of study drug up to Day 45

  2. Number of Participants With Adverse Events (AEs) According to Severity

    Severity will be assessed according to the following scale: Mild, moderate and severe.

    Time frame: From the first dose of study drug up to Day 45

  3. Number of Participants With Change From Baseline in Clinically Significant Vital Sign Parameters

    Time frame: Baseline up to Day 45

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Parameters

    Time frame: From the first dose of study drug up to Day 45

  5. Number of Participants With Change From Baseline in Clinically Significant Clinical Laboratory Evaluations

    Time frame: From the first dose of study drug up to Day 45

  6. Number of Participants With Columbia-Suicide Severity Rating Scale (C-SSRS) Responses

    The suicidal ideation and behavior will be monitored during the study using the C-SSRS. This scale consists of a "Baseline/Screening" version that assesses the lifetime and recent experience of the participant with suicidal ideation and behavior, and a "Since Last Visit" version that focuses on suicidality since the last study visit. The C-SSRS includes "yes" or "no" responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe).

    Time frame: Baseline up to Day 45

  7. Change From Baseline in Glasgow Coma Scale (GCS) Score

    The GCS is a simple measure of the depth and duration of impaired consciousness and coma. 3 domains of alertness will be evaluated: eye opening response (scored 1 \[None\] to 4 \[Spontaneous\]), verbal response (scored 1 \[None\] to 5 \[Oriented\]), and motor response (scored 1 \[None\] to 6 \[Obeys commands\]). Total scores range from 3 to 15, with 15 reflecting full alertness.

    Time frame: Baseline up to Day 45

  8. Change From Baseline in Stanford Sleepiness Scale (SSS) Score

    The SSS is a participant-rated measure of sleepiness, frequently used for both research and clinical purposes. The SSS evaluates sleepiness at specific moments in time. Respondents rate their current degree of sleepiness and alertness on a scale of 1 to 7, where the lowest score of '1' indicates the respondent is 'feeling active, vital, alert, or wide awake' and the highest score of '7' indicates the respondent is 'no longer fighting sleep, sleep onset soon; having dream-like thoughts'.

    Time frame: Baseline up to Day 45

  9. PK of Brexanolone: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1- Day 45

  10. PK of Brexanolone: Time to Reach Cmax (Tmax)

    Time frame: Day 1- Day 45

  11. PK of Brexanolone: Area Under the Concentration-time Curve From Time 0 to Last Measurable Concentration (AUC0-last)

    Time frame: Day 1- Day 45

  12. PK of Brexanolone: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf)

    Time frame: Day 1- Day 45

  13. PK of Brexanolone: Apparent Terminal Elimination Half-life (t½)

    Time frame: Day 1- Day 45

  14. PK of Brexanolone: Apparent Clearance (CL/F)

    Time frame: Day 1- Day 45

  15. PK of Brexanolone: Volume of Distribution (Vz/F)

    Time frame: Day 1- Day 45

Secondary outcomes

  1. Change From Baseline in Hamilton Depression Rating Scale (HAM-D) Total Score

    The 17-item HAM-D will be used to rate the severity of depression in participants who are already diagnosed as depressed. The 17-item HAM-D is comprised of individual ratings related to the following symptoms: depressed mood (sadness, hopeless, helpless, and worthless), feelings of guilt, suicide, insomnia (early, middle, and late), work and activities, retardation (slowness of thought and speech, impaired ability to concentrate, and decreased motor activity), agitation, anxiety (psychic and somatic), somatic symptoms (gastrointestinal and general), genital symptoms, hypochondriasis, loss of weight, and insight. The total scores range from 0-52. Higher score indicates more depression.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  2. Number of Participants With HAM-D Response

    Response is defined as \>=50 percent (%) reduction from baseline in HAM-D total score. The HAM-D is a 17-item scale used to rate the severity of depression in participants who are already diagnosed as depressed. The total scores of HAM-D range from 0-52. Higher score indicates more depression.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  3. Number of Participants With HAM-D Remission

    Remission is defined as \<=7.0 HAM-D total score. The HAM-D is a 17-item scale used to rate the severity of depression in participants who are already diagnosed as depressed. The total scores of HAM-D range from 0-52. Higher score indicates more depression.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  4. Number of Participants With Clinical Global Impression - Improvement (CGI-I) Response

    The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition posttreatment. The clinician will rate the participant's total improvement, whether or not it is due entirely to investigational product treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. CGI-I response will be defined as having a CGI-I score of "very much improved" or "much improved."

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  5. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Response

    The CGI-S item uses a 7- point Likert scale to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating. Choices include: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = extremely ill.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  6. Change From Baseline in HAM-D Bech-6 Subscale Score

    The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores will be transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  7. Change From Baseline in HAM-D Individual Item Score

    The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

  8. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

    The 14-item HAM-A will be used to rate the severity of symptoms of anxiety. Each of the 14 items is defined by a series of symptoms and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Scoring for the HAM-A is calculated by assigning scores of 0 (not present) to 4 (very severe), with a total score range of 0 to 56, where less than (\<) 17 indicates mild severity, 18 to 24 mild to moderate severity, and 25 to 30 moderate to severe severity. The HAM-A total score will be calculated as the sum of the 14 individual item scores.

    Time frame: Baseline and at Days 2, 3, 4, 8, 15, 30, and 45

07

Study locations

11 sites
  • Cenexel CNR
    Sherman Oaks, California 91403, United States
  • CenExel CNS-Torrance
    Torrance, California 90504, United States
  • Clinical Research Center of Florida
    Boynton Beach, Florida 33435, United States
  • Aventura Clinical Research, LLC
    Davie, Florida 33328, United States
  • South Florida Research Phase I-IV Inc
    Miami Springs, Florida 33166, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • Cenexel ACMR Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta, LLC
    Decatur, Georgia 30030, United States
  • Research Carolina Elite
    Denver, North Carolina 28037, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • Maximos OB/GYN
    League City, Texas 77573, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Mar 2024, 5 months.

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Sep 29, 2023
Primary completionActual
Mar 13, 2024
CompletionActual
Mar 13, 2024
Results delay requested
Jan 13, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057012
Lead sponsor
Brii Biosciences Limited
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Sep 29, 2023
Primary completion
Mar 13, 2024
Completion
Mar 13, 2024
Last update
Jan 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion